PolTREG S.A. (PTG) - Total Liabilities
Based on the latest financial reports, PolTREG S.A. (PTG) has total liabilities worth zł30.71 Million PLN (≈ $8.45 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See PTG current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
PolTREG S.A. - Total Liabilities Trend (2018–2024)
This chart illustrates how PolTREG S.A.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PTG total asset value.
PolTREG S.A. Competitors by Total Liabilities
The table below lists competitors of PolTREG S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Perimeter Medical Imaging AI Inc
V:PINK
|
Canada | CA$2.51 Million |
|
Progressive Planet Solutions Inc
V:PLAN
|
Canada | CA$11.35 Million |
|
Ocean Vantage Holdings Bhd
KLSE:0220
|
Malaysia | RM19.88 Million |
|
YSX Tech. Co., Ltd Class A Ordinary Shares
NASDAQ:YSXT
|
USA | $16.96 Million |
|
Electro-Sensors Inc
NASDAQ:ELSE
|
USA | $885.00K |
|
BayWa Aktiengesellschaft
F:BYW
|
Germany | €9.76 Billion |
|
Sc Engineering
KO:023960
|
Korea | ₩71.82 Billion |
|
System1 Inc
NYSE:SST
|
USA | $387.55 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down PolTREG S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See PTG equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PolTREG S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PolTREG S.A. (2018–2024)
The table below shows the annual total liabilities of PolTREG S.A. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł33.15 Million ≈ $9.12 Million |
-16.26% |
| 2023-12-31 | zł39.58 Million ≈ $10.89 Million |
+77.77% |
| 2022-12-31 | zł22.27 Million ≈ $6.13 Million |
+263.93% |
| 2021-12-31 | zł6.12 Million ≈ $1.68 Million |
+79.41% |
| 2020-12-31 | zł3.41 Million ≈ $938.48K |
-50.23% |
| 2019-12-31 | zł6.85 Million ≈ $1.89 Million |
-29.37% |
| 2018-12-31 | zł9.70 Million ≈ $2.67 Million |
-- |
About PolTREG S.A.
Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis. The company was incorporated in 2016 and is based in Gdansk, Poland.